Kamada (KMDA) Other Accumulated Expenses (2016 - 2022)
Kamada's (KMDA) quarterly Other Accumulated Expenses came in at -$30000.0 in Q4 2022, little changed on a YoY basis from -$30000.0 in Q4 2021, and little changed quarter-over-quarter from -$30000.0 in Q4 2021.
Powered by 
Analysis
Kamada (KMDA) Other Accumulated Expenses (2016 - 2022) Analysis & Trends
Kamada (KMDA) has reported Other Accumulated Expenses for 3 consecutive years, with -$30000.0 the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Other Accumulated Expenses changed 0.0% year-over-year to -$30000.0; the trailing twelve-month figure through Dec 2022 stood at -$30000.0 (changed 0.0% YoY), and the FY2022 full-year result was -$30000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses held at -$30000.0 in Q4 2022 per KMDA's latest filing, from -$30000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at -$30000.0 in Q4 2021 and bottomed at -$30000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.39 Bn | 197.40 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.14 Bn | 177.96 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.55 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.39 Bn | 49.25 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.43 Bn | 31.12 Bn | 992.69 Mn |
| 8 | Biogen | 31.18 Bn | 29.89 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn |
| 10 | Kamada | 472.70 Mn | 402.57 Mn | 22.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -30,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Dec 31, 2016 | 321,000.00 |